

# Exploring alternative wound care treatment for percutaneous gastrostomy site infection: A prospective, randomized, open, blinded end-point (PROBE) design.

No registrations found.

<b>Ethical review</b>	Not applicable
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON23605

### Source

Nationaal Trial Register

### Brief title

PEG- Protocol

### Health condition

PEG-site infections

Infectie van de PEG-insteekopening

## Sponsors and support

**Primary sponsor:** VU Medical Center, Amsterdam

**Source(s) of monetary or material Support:** Initiator

## Intervention

## Outcome measures

### Primary outcome

The primary outcome will be the reduction or increase in peristomal sepsis scoring in both groups using the scoring scale of Jain et al.

### Secondary outcome

1. The number of patients in which the PEG - site infection was regarded as healed;
2. Percentage decrease in number of bacterial species as measured by the IS-pro;
3. Treatment related adverse events;
4. Recurrence of infection 1 week after healing;
5. Deterioration of the infection-site that will require withdrawal.

## Study description

### Background summary

To determine the efficacy of silver impregnated dressings compared to a topical antibiotic to treat patients with PEG-site infections.

### Study objective

Modern dressings containing silver are more effective than topical antibiotic treatment for healing of PEG-site infections.

### Study design

The primary endpoint will be evaluated by a blinded assessor two weeks after treatment.

### Intervention

Group 1: Standard treatment with local antibiotic ointment (Fucidin ointment);

Group 2: Treatment with silver-impregnated dressing (Atrauman AG).

## Contacts

### **Public**

De Boelelaan 1118  
Esmé Clasquin  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20 4449455

### **Scientific**

De Boelelaan 1118  
Esmé Clasquin  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20 4449455

## Eligibility criteria

### **Inclusion criteria**

1. Signed informed consent;
2. PEG-site infection graded as type 1 & 2 (1= early signs of inflammation, proactive measures, 2= Requiring local antiseptic/antibiotic care);
3. Male and female participants age 18 and older;
4. PEG insertion procedure longer than 1 week prior to randomization;
5. Patient or guardian is able to fully comprehend and perform study procedures.

### **Exclusion criteria**

1. Estimated life expectancy less than one month;
2. Concurrent use of oral antibiotics for other diagnosis;
3. Signs and symptoms of concurrent disease for which the subject is expected to start antibiotic treatment.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-02-2011
Enrollment:	30
Type:	Actual

## Ethics review

Not applicable	
Application type:	Not applicable

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL2549
NTR-old	NTR2667
Other	: GE10-09
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Study results

### Summary results

N/A